VEGFA and diabetes mellitus: It is well established that it is difficult to stimulate angiogenesis in diabetes, making this a challenging, and clinically relevant, test for our system.[55, 56, 57, 58] The actuation‐meditated release of VEGF from the SRDD system in the hyperglycemic rats resulted in a significant increase in CD31+ blood vessel number and length density at implant sites compared to the passive release VEGF controls.